Business context and reporting period
Prestige Brands Holdings, Inc. filed this unaudited Form 10-Q for the fiscal third quarter ended December 31, 2016, and the nine months then ended. The company markets OTC healthcare and household-cleaning products. The requested company name, Prestige Consumer Healthcare Inc., does not match the registrant name shown on this filing; verify the entity and filing identification.
Financial performance and position
| Metric | Three months ended Dec. 31, 2016 | Year-over-year change | Nine months ended Dec. 31, 2016 | Year-over-year change |
|---|---|---|---|---|
| Total revenue | $216.8 million | +8.3% | $641.4 million | +7.2% |
| Gross profit / margin | $124.5 million / 57.5% | Margin down 0.8 percentage points | $370.1 million / 57.7% | Margin down 0.6 points |
| Operating income | $69.3 million | +10.6% | $152.6 million | Down 21.8% |
| Net income | $31.6 million | +13.0% | $58.3 million | Down 32.2% |
| Diluted EPS | $0.59 | Up from $0.53 | $1.09 | Down from $1.62 |
Quarterly operating margin was approximately 32.0% versus 31.3% a year earlier; nine-month operating margin was 23.8% versus 32.6%, reflecting the current-period divestiture loss. Quarterly net margin was approximately 14.6% versus 14.0%; nine-month net margin was 9.1% versus 14.4%.
- Cash flow: Nine-month operating cash flow was $140.3 million, compared with $136.5 million. Investing cash flow provided $110.3 million, primarily from $110.7 million in divestiture proceeds. Financing used $212.7 million, including term-loan and revolver repayments. Cash ended at $63.3 million, up from $27.2 million at March 31, 2016.
- Liquidity: Current assets were $291.2 million and current liabilities $132.3 million (current ratio approximately 2.2). The company reported $135 million of available ABL revolving capacity and no revolver borrowings at December 31.
- Debt: Principal debt was $1.437 billion, down from $1.653 billion at March 31; net debt, using reported cash, was approximately $1.374 billion. Interest expense for the nine months was $60.7 million. The company reported compliance with debt covenants at quarter-end.
Material changes versus the prior comparable period
- DenTek, acquired in February 2016, contributed about $17.3 million of quarterly revenue and $51.2 million for the nine-month period that was not in the respective prior-year comparisons. Excluding DenTek, management said revenue in the North American OTC segment declined, including weakness in several product groups.
- Nine-month operating results included a $51.6 million net pre-tax divestiture loss, mainly from selling Pediacare, New Skin and Fiber Choice. December sales of e.p.t. and Dermoplast produced a $3.9 million gain. These items substantially explain the decline in nine-month operating income and net income.
- The company sold remaining Comet license rights for $11.0 million in August and recorded a $1.2 million gain. The sale ended future royalties for those rights, contributing to lower Household Cleaning revenue and margins.
- At December 31, goodwill and intangible assets totaled approximately $2.502 billion, down from $2.683 billion at March 31, largely reflecting asset sales and currency movements.
Outlook, commentary, risks and unusual items
- Management said operating cash generation and existing credit facilities should be adequate for working capital and capital expenditures over the next 12 months, excluding acquisitions; it cautioned that this is not assured. No revenue or earnings guidance is provided in the supplied filing text. The estimated effective tax rate for the remaining fiscal 2017 quarter was approximately 35.1%, excluding Fleet acquisition effects and discrete items.
- After quarter-end, on January 26, 2017, the company completed its $825 million Fleet acquisition, adding brands including Summer’s Eve, Fleet and Pedia-Lax. It funded the transaction with cash, revolving borrowings and a new $740 million incremental term loan, alongside refinancing existing term debt. Purchase accounting was incomplete, and management expected a material effect on subsequent-period results. This transaction materially changes the post-quarter debt and business profile.
- Key risks include high leverage and floating-rate exposure (a 1 percentage-point rate increase was estimated to reduce pre-tax earnings and cash flow by about $1.8 million for the quarter and $5.9 million for the nine months), sales concentration, reliance on third-party manufacturers and a major distribution center, foreign currency exposure, and potential impairment of substantial goodwill and intangible assets.
- Walmart and Walgreens each accounted for more than 10% of gross revenue in at least some periods; together they represented about 36.2% of quarter-end receivables. Substantially all cash balances were uninsured. The filing also disclosed an error in prior-period subsidiary consolidating statements from intercompany transactions; management concluded it did not affect consolidated statements or consolidated cash flow and was not material to the consolidated interim financial statements.
Important facts for investors to verify
- Confirm the registrant/entity match: the filing identifies Prestige Brands Holdings, Inc., not Prestige Consumer Healthcare Inc.
- Assess the Fleet acquisition’s finalized purchase-price allocation, financing, post-close debt, interest costs and integration performance.
- Separate underlying operating trends from acquisition contributions and divestiture gains/losses, especially in North American OTC and Household Cleaning.
- Monitor covenant headroom, floating-rate exposure, cash availability and the company’s ability to reduce debt after Fleet.
- Review customer and supplier concentration, uninsured cash balances, and assumptions supporting the carrying values of goodwill and intangible assets.